Generated: October 20, 2017
DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 202941
, which is a drug marketed by Mylan Pharms Inc, Apotex, Lupin Ltd, Cipla Ltd, Aurobindo Pharma Ltd, Apotex Inc, Hetero Labs Ltd V, Silarx Pharms Inc, Appco Pharma Llc, Eci Pharms Llc, Pharmacare, Hetero Labs Ltd Iii, Strides Pharma, and Teva Pharms, and is included in twenty-three NDAs. It is available from twenty suppliers. Additional details are available on the LAMIVUDINE profile page.
The generic ingredient in LAMIVUDINE is lamivudine; zidovudine. There are twenty-eight drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the lamivudine; zidovudine profile page.
Summary for NDA: 202941
|Formulation / Manufacturing:||see details|
Pharmacology for NDA: 202941
Complete Access Available with Subscription
Summary for product number 001
|Approval Date:||Jan 2, 2014||TE:||AB||RLD:||No|
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.